glp-1 market news november 2025 Receptor Agonist Size, Share, Growth, 2034 GLP-1 Weight-Loss Drugs Ride Health,

The search strategy combines Medical Subject Headings (MeSH) and keywords including GLP-1, glucagon-like peptide-1 receptor, GLP-1 receptor agonist, sepsis, systemic inflammation, infection, immune response, critical illness, MODS, multiple organ dysfunction, cytokines and sepsis treatment. Articles were screened for relevance based on titles and abstracts, with full-text evaluation of studies addressing the mechanistic or therapeutic implications of GLP-1 signaling in experimental or clinical models of sepsis

This segment is driving demand for medically guided nutrition aligned with weight loss and glycemic control needs

A representative from Novo Nordisk, the manufacturer of Ozempic and Wegovy, told The New York Post they had received reports of abnormal dreams from users, but since these adverse events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. They added, Novo Nordisk does not have all information pertaining to the patients treatment plan, concomitant medications, and medical conditions

This changed after Dupr joined Roger Unger (figure 15), an American endocrinologist at the University of Texas Southwestern Medical Center in Dallas with a strong interest in glucagon and diabetes

[DOI] [PMC free article] [PubMed] [Google Scholar] 32.Lean M.E., Carraro R., Finer N., Hartvig H., Lindegaard M.L., Rssner S., et al

7g of fiber and 14g of protein per serving*